mtp inhibitor

Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.

BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.

Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.

Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

Implitapide Racemate, the racemate of Implitapide, is an inhibitor of microsomal triglyceride transfer protein (MTP).

CP-319340 free base is an inhibitor of microsomal triglyceride transfer protein (MTP).

Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).

PF-02575799 is an inhibitor of microsomal triglyceride transfer protein (MTP) (IC50: 0.77±0.29 nM).

Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.

CP-346086 dihydrate is a potent, orally active inhibitor of microsomal triglyceride transfer protein (MTP), with an IC50 of 2.0 nM for both human and rodent MTP, effectively lowering plasma cholesterol and triglyceride levels in vivo.

CP-346086 is a highly potent and orally bioavailable inhibitor of microsomal triglyceride transfer protein (MTP), exhibiting an IC50 value of 2.0 nM against both human and rodent MTP. This compound effectively reduces plasma levels of cholesterol and triglycerides when administered in vivo.

CP-10447 is an inhibitor apolipoprotein B (apoB) and triglyceride secretion in human hepatoma cells (HepG2) by inhibiting MTP activity and stimulating the early ER degradation of apoB. It is useful tool for further study of the mechanisms of apoB secretion and triglyceride-rich lipoprotein assembly.

MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation. Further, it inhibits JAK2 signaling, rendering it useful for the study of oral squamous cell carcinoma [1].